Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology
Thoracic Oncology CRT
- Deliver the best state of the art clinical care
- Improve integration of clinical and research programs
- Conduct high impact clinical trials
- Increase peer reviewed clinical projects and funding
- Engage basic scientists in clinical issues and paradigms
- Build clinical/basic science teams to move toward team science and funding
- Continue bench to bedside translational and reverse translational research
- Develop more investigator initiated trials to take advantage of the immune profiling laboratory
- Increased involvement of Care Centers
- Seek greater number and involvement with surgical trials
- Foster more intra-programmatic grants (P01s)
- Develop new combination trials with immunotherapy and phase I targets
Leadership
- Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale. She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and brain metastases. Learn more about Dr. Sarah Goldberg>>
Members
Associate Professor; Associate Cancer Center Director, Clinical Initiatives
I currently serve as an Associate Professor of Medicine in the Section of Medical Oncology, specializing in thoracic oncology, with a background in translational research in metastasis, as well as extensive experience in clinical practice in both academic and community settings. My clinical focus has been to build a small cell lung cancer program at Yale with a comprehensive portfolio of clinical trials testing novel therapeutics for these patients. My research interests focus on development of clinical trials and translational studies to test novel agents and combinations with immune checkpoint inhibitors for both small cell and non-small cell lung tumors. I have helped to build our SCH Network and oversee operations, quality efforts and clinical research in our Smilow Care Centers. I have a particular focus in quality measurement and improvement and have worked to achieve ASCO QOPI Certification for the entire Smilow academic clinical practice. I have spearheaded quality initiatives locally and nationally for ASCO. I am dedicated to quality improvement for patient-centered cancer services, and champion the use of patient-reported outcomes. Learn more about Dr. Anne Chiang>>Professor of Internal Medicine (Medical Oncology); Chief, Thoracic Medical Oncology
Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy and targeted therapy for non-small cell lung cancer. He currently leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary translational research interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies.Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology
Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale. She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and brain metastases. Learn more about Dr. Sarah Goldberg>>Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Program Director, Master of Health Science - Clinical Investigation Track (MHS-CI)
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Learn more about Dr. Herbst >> Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have revolutionized the field and greatly enhanced patient survival. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. His leadership in targeted therapeutics resulted in being selected for ASCO’s plenary presentation in 2020 and 2023 and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine. In 2015 and again in 2020, his team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the National Cancer Institute (NCI), which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies. His work has also been funded by ASCO, AACR, the United States Department of Defense, and by an AACR/ Stand Up to Cancer Dream Team grant. His work on "umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and was the founding principal investigator (PI) of the Lung Master Protocol (Lung-MAP), a position he held for ten years. He testified on this before the House of Representatives 21st Century Cures committee and serves as a prominent figure in this area. He has served over ten years as a member of the National Academy of Medicine’s Cancer Policy Forum, for which he organized several meetings focused on policy issues in personalized medicine and tobacco control. He is now serving his second term on the National Academy of Medicine’s Cancer Policy Forum. He is currently the Vice Chair for the Southwestern Oncology Group (SWOG) Lung Committee and chair emeritus and special advisor for the Lung-MAP trial. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Prior to his appointment at Yale, Dr. Herbst was the Barnhart Distinguished Professor and Chief of the Section of Thoracic Medical Oncology in the Department of Thoracic/Head and Neck Medical Oncology, at The University of Texas M.D. Anderson Cancer Center (UT-MDACC) in Houston, Texas. He also served as Professor in the Department of Cancer Biology and Co-Director of the Phase I Clinical Trials Program. Dr. Herbst is a highly respected clinician scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has authored or co-authored more than 450 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. He is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where serves as Chair of the AACR Scientific Policy and Government Affairs Committee. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. In 2019, he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors and the board of directors of the American Association of Cancer Research(AACR). He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy. Dr. Herbst is the recipient of the 2022 Giants of Cancer Care® award for Lung Cancer and was honored by Friends of Cancer Research in 2022 as one of their 25 scientific and advocacy leaders who, through their work and partnership, have been instrumental over the course of the last 25 years in making significant advancements for patients. Over the course of his career, Dr. Herbst has worked to bring novel therapies to the treatment of non-small cell lung cancer, bringing us closer to curing this disease.Assistant Professor
So Yeon Kim, MD, is an Assistant Professor of Medicine (Medical Oncology) at Yale School of Medicine. Dr. Kim completed her undergraduate studies at Princeton University and received her medical degree from Albert Einstein College of Medicine. She completed her internal medicine residency at Tufts Medical Center and completed her hematology oncology fellowship at Montefiore Medical Center. Dr. Kim's clinical practice is focused primarily on caring for patients with thoracic malignancies. In 2022, she received the ASCO Merit Award based on her research on MET exon14 skipping mutations in non-small cell lung cancer. Her ongoing research interests include targeted treatment and immunotherapy approaches in lung cancer.Associate Professor of Therapeutic Radiology; Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, PET-Guided Radiotherapy Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory House, Purple House, Office of Student Affairs
Dr. Henry S. Park is a board-certified radiation oncologist who serves as associate professor, vice chair for clinical research, chief of thoracic radiotherapy, and chief of PET-guided radiotherapy for the Department of Therapeutic Radiology at the Yale School of Medicine. For the Yale Cancer Center, he is an assistant medical director of the Clinical Trials Office, through which he leads the radiation oncology committee and is associate leader of the lung clinical research team. For the medical school's Office of Student Affairs, he is the head of one of the six advisory houses. He has previously held roles as the associate residency program director, medical student electives director, and continuing medical education director for radiation oncology. Dr. Park received his undergraduate degree from Yale College, master's degree from the Harvard School of Public Health, and medical doctorate degree from the Yale School of Medicine. He completed his internal medicine internship at Harvard Medical School's Beth Israel Deaconess Medical Center before returning to Yale New Haven Hospital for his residency and chief residency in radiation oncology. Dr. Park subspecializes in radiation therapy for lung cancer and head and neck cancer, maintaining a busy clinical practice in New Haven. He leads a wide-ranging research program in clinical trials, real-world evidence, and health services. He has co-authored over 135 peer-reviewed original research articles and 45 reviews, book chapters, invited editorials, and practice guidelines. He serves as an oral and written boards examiner for the American Board of Radiology and as an active committee member for the American Society for Radiation Oncology, American Radium Society, SWOG, ECOG-ACRIN, and NRG. He has been honored with multiple awards for his contributions to patient care, clinical research, and medical education. Learn more about Dr. Park>>Assistant Professor
Dr. Wilson graduated from Duke University and received his PhD at Yale University and MD at Harvard Medical School. He completed an internship and residency at Brigham and Women's Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He completed a research fellowship at Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. His research focuses on the identification and characterization of genetic vulnerabilities in cancer as well as genetic determinants of sensitivity and resistance to targeted therapies.